ACADIA Pharmaceuticals (ACAD) Awarded Grant From Michael J. Fox Foundation
More News related to ACAD
- Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c
- ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
- ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
- ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
- ACADIA Pharma (ACAD) to Cut Workforce by 50%
More News related to Corporate News
- S&P Announces Changes to US Index: CMN for NTG, CVGW for STSA
- Kinross (KGC) Enters Agreement for $125M Letter of Credit Facility
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Trubion Pharma (TRBN) Announces Two Presentations of TRU-016 Product at 2009 ASH Meeting
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) has been awarded a grant from The Michael J. Fox Foundation for the development of novel estrogen receptor beta (ER-beta) agonists for the treatment of Parkinson's disease. The grant of up to $830,000 was awarded under the Foundation's Therapeutics Development Initiative aimed at supporting preclinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms above and beyond current standards of care.
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
